External Trigeminal Nerve Stimulation Device Launched for Pediatric ADHD

Bioelectronics company NeuroSigma Inc. recently announced the commercial launch of a bioelectronic medical device that uses external trigeminal nerve stimulation (eTNS) to treat children with attention-deficit/hyperactivity disorder (ADHD). The Monarch eTNS System was the first nondrug treatment cleared by the US Food and Drug Administration (FDA) for treating pediatric ADHD in 2019.

“Given emerging shortages of leading ADHD medications in the United States, the launch of a nondrug alternative to potentially addictive pharmaceutical stimulants is even more imperative in expanding long-term therapeutic options,” said Ian Cook, MD, chief medical officer of NeuroSigma.

Related: Stimulant Shortage the Result of a “Perfect Storm”

The launch includes a copay program that allows commercially insured children between the ages of 7 and 12 with an ADHD diagnosis to obtain the Monarch eTNS System and the first month’s supply of disposable NS-2 electric patches for $100. The copay for each additional month of patches is $40.

“NeuroSigma’s mission is to facilitate access to eTNS therapy for the millions of children worldwide struggling with ADHD,” said Colin Kealey, MD, president of NeuroSigma. “Our new Pediatric Care Co-Pay Program is an important milestone towards achieving this goal and will significantly increase the affordability of our therapy for eligible patients and their caregivers in the United States.”
 

Reference

NeuroSigma announces commercial launch of the Monarch eTNS System for the treatment of pediatric ADHD at annual meeting of the American Academy of Child and Adolescent Psychiatry. News release. NeuroSigma Inc.; October 17, 2022. Accessed October 28, 2022.